Markousis-Mavrogenis G, et al. - Using the BIOSTAT-CHF cohort, researchers investigated and characterized the link between interleukin (IL)-6 and clinical features, outcomes, and other inflammatory biomarkers in heart failure (HF). The study sample consisted of 2,329 patients (89.4% with a left ventricular ejection fraction [LVEF] ≤ 40%). All-cause mortality and HF hospitalization during 2 years was considered to be the primary outcome. Secondary outcomes included all-cause, cardiovascular (CV), and non-CV mortality. More than 50% of patients in this large, heterogeneous HF cohort had elevated IL-6 levels. Iron deficiency, reduced LVEF, atrial fibrillation, and poorer clinical outcomes were found to be related to elevated IL-6 levels among participants.